| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
91,540,000 |
| Market
Cap: |
34.79(M) |
| Last
Volume: |
1,296,467 |
Avg
Vol: |
1,292,882 |
| 52
Week Range: |
$0.38 - $0.9341 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Curis is a biotechnology company focused on the development of therapeutics for the treatment of cancer. Co.'s clinical stage drug candidates are: Emavusertib, which is being tested in a Phase 1/2 dose escalating clinical trial in patients with non-Hodgkin lymphomas; CI-8993, which is a monoclonal antibody; Fimepinostat, which is a small molecule that potently inhibits the activity of histone deacetylase, and phosphotidyl-inositol 3 kinase; CA-170, for which Co. has announced initial data from a clinical study in patients with mesothelioma in conjunction with the Society of lmmunotherapy of Cancer; and CA-327, which is a small molecule antagonist of PDL1 and TIM3.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Noel Mark |
VP, Tech Management |
• – – |
2007-06-14 |
5 |
A |
$1.03 |
$3,000 |
D/D |
2,913 |
0 |
|
- |
|
| Qian Changgeng |
VP, Research & Preclinical Dev |
• – – |
2007-06-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,014 |
|
- |
|
| Bayh Susan B |
Director |
– • – |
2007-06-06 |
4 |
A |
$0.01 |
$100 |
D/D |
10,000 |
20,000 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2007-06-06 |
4 |
A |
$0.01 |
$100 |
D/D |
10,000 |
824,035 |
|
- |
|
| Greenacre Martyn D |
Director |
– • – |
2007-06-06 |
4 |
A |
$0.01 |
$100 |
D/D |
10,000 |
35,138 |
|
- |
|
| Tobin James R |
Director |
– • – |
2007-06-06 |
4 |
A |
$0.01 |
$100 |
D/D |
10,000 |
92,477 |
|
- |
|
| Kaitin Kenneth I |
Director |
– • – |
2007-06-06 |
4 |
A |
$0.01 |
$100 |
D/D |
10,000 |
20,000 |
|
- |
|
| Davie Joseph M |
Director |
– • – |
2007-06-06 |
4 |
A |
$0.01 |
$100 |
D/D |
10,000 |
20,000 |
|
- |
|
| Bayh Susan B |
Director |
– • – |
2007-03-27 |
4 |
S |
$1.66 |
$1,660 |
D/D |
(1,000) |
10,000 |
|
- |
|
| Noel Mark |
VP, Tech Management |
• – – |
2006-12-14 |
5 |
A |
$1.04 |
$3,005 |
D/D |
2,889 |
17,797 |
|
- |
|
| Passeri Daniel R |
CEO and Director |
• • – |
2006-08-17 |
4 |
A |
$1.01 |
$25,480 |
D/D |
25,000 |
35,000 |
|
- |
|
| Noel Mark |
VP, Tech Management |
• – – |
2006-06-14 |
5 |
A |
$1.39 |
$2,925 |
D/D |
2,104 |
0 |
|
- |
|
| Bayh Susan B |
Director |
– • – |
2006-06-01 |
4 |
A |
$0.01 |
$100 |
D/D |
10,000 |
11,000 |
|
- |
|
| Davie Joseph M |
Director |
– • – |
2006-06-01 |
4 |
A |
$0.01 |
$100 |
D/D |
10,000 |
10,000 |
|
- |
|
| Passeri Daniel R |
CEO and Director |
• • – |
2006-05-31 |
4 |
A |
$0.01 |
$100 |
D/D |
10,000 |
10,000 |
|
- |
|
| Noel Mark |
VP, Tech Management |
• – – |
2005-12-14 |
5 |
A |
$3.07 |
$2,926 |
D/D |
953 |
12,804 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2005-09-18 |
4 |
OE |
$2.43 |
$136,173 |
D/D |
54,688 |
804,035 |
|
- |
|
| Noel Mark |
VP, Tech Management |
• – – |
2005-08-02 |
4 |
S |
$4.84 |
$3,388 |
D/D |
(700) |
0 |
|
- |
|
| Noel Mark |
VP, Tech Management |
• – – |
2005-08-02 |
4 |
OE |
$0.84 |
$588 |
D/D |
700 |
700 |
|
- |
|
| Noel Mark |
VP, Tech Management |
• – – |
2005-07-29 |
4 |
S |
$4.84 |
$20,852 |
D/D |
(4,300) |
0 |
|
- |
|
| Noel Mark |
VP, Tech Management |
• – – |
2005-07-29 |
4 |
OE |
$0.84 |
$3,612 |
D/D |
4,300 |
4,300 |
|
- |
|
| Passeri Daniel R |
Chief Executive Officer |
• – – |
2005-07-20 |
4 |
S |
$4.50 |
$34,219 |
D/D |
(7,600) |
0 |
|
- |
|
| Passeri Daniel R |
Chief Executive Officer |
• – – |
2005-07-20 |
4 |
OE |
$1.50 |
$11,400 |
D/D |
7,600 |
7,600 |
|
- |
|
| Passeri Daniel R |
Chief Executive Officer |
• – – |
2005-07-19 |
4 |
S |
$4.50 |
$46,432 |
D/D |
(10,300) |
0 |
|
- |
|
| Passeri Daniel R |
Chief Executive Officer |
• – – |
2005-07-19 |
4 |
OE |
$1.50 |
$15,450 |
D/D |
10,300 |
10,300 |
|
- |
|
303 Records found
|
|
Page 7 of 13 |
|
|
